{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:54:20Z","timestamp":1781902460505,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DBT Glue Grant","award":["BT\/PR23078\/MED\/29\/1253\/2017"],"award-info":[{"award-number":["BT\/PR23078\/MED\/29\/1253\/2017"]}]},{"DOI":"10.13039\/501100001843","name":"SERB","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"crossref"}]},{"name":"IISc-DBT partnership programme","award":["DBT\/BF\/PR\/INS\/2011-12\/IISc"],"award-info":[{"award-number":["DBT\/BF\/PR\/INS\/2011-12\/IISc"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Small molecule inhibitors targeting BCL2 are explored as anticancer therapeutics. Previously, we have reported identification and characterization of a novel BCL2 inhibitor, Disarib. Disarib induced cancer cell death in a BCL2 dependent manner in different cancer cell lines and mouse tumor models when it was administered intraperitoneally. In the present study, using two syngeneic mouse models, breast adenocarcinoma (EAC) and Dalton\u2019s lymphoma (DLA), we show that oral administration of Disarib resulted in significant tumor regression in a concentration dependent manner. Importantly, tumor developed in both female and male mice were equally sensitive to Disarib. Further, we have investigated the toxicity of Disarib in normal cells. Single dose toxicity analysis of Disarib in male and female mice after oral administration revealed no significant variations compared to control group for parameters such as body weight, food and water consumption and behavioural changes which were analysed for the entire period of study. Haematological and histopathological analyses also did not show any significant difference from the control groups. Thus, our results reveal safe use of Disarib as a small molecule inhibitor and provide the foundation for investigation of other preclinical studies.<\/jats:p>","DOI":"10.1038\/s41598-020-72058-8","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T10:03:22Z","timestamp":1600250602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Acute toxicity analysis of Disarib, an inhibitor of BCL2"],"prefix":"10.1038","volume":"10","author":[{"given":"Shivangi","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kontham Kulangara","family":"Varsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana Elizabeth","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibha","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kempegowda","family":"Mantelingu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathees C.","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"72058_CR1","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1535-7163.MCT-16-0031","volume":"15","author":"RS Soderquist","year":"2016","unstructured":"Soderquist, R. S. & Eastman, A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol. Cancer Ther. 15, 2011\u20132017 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"72058_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fonc.2018.00645","volume":"8","author":"B Tessoulin","year":"2018","unstructured":"Tessoulin, B. et al. BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker. Front. Oncol. 8, 645 (2018).","journal-title":"Front. Oncol."},{"key":"72058_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.cdd.4401987","volume":"13","author":"S Zinkel","year":"2006","unstructured":"Zinkel, S., Gross, A. & Yang, E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 13, 1351\u20131359 (2006).","journal-title":"Cell Death Differ."},{"key":"72058_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bbcan.2017.06.004","volume":"1868","author":"G Radha","year":"2017","unstructured":"Radha, G. & Raghavan, S. C. BCL2: a promising cancer therapeutic target. Biochim. Biophys. Acta Rev. Cancer 1868, 309\u2013314 (2017).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"72058_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ceca.2017.05.014","volume":"70","author":"T Vervloessem","year":"2018","unstructured":"Vervloessem, T. et al. Bcl-2 inhibitors as anti-cancer therapeutics: the impact of and on calcium signaling. Cell Calcium 70, 102\u2013116 (2018).","journal-title":"Cell Calcium"},{"key":"72058_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini, G. F., Ribeiro, G. N., Pinto Neto, J. V., Campos, L. T. & Hamerschlak, N. BCL-2 as therapeutic target for hematological malignancies. J. Hematol. Oncol. 11, 65 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"72058_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"ARD Delbridge","year":"2015","unstructured":"Delbridge, A. R. D. & Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 22, 1071\u20131080 (2015).","journal-title":"Cell Death Differ."},{"key":"72058_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.tcb.2008.01.007","volume":"18","author":"JE Chipuk","year":"2008","unstructured":"Chipuk, J. E. & Green, D. R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 18, 157\u2013164 (2008).","journal-title":"Trends Cell Biol."},{"key":"72058_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1242\/jcs.031682","volume":"122","author":"JK Brunelle","year":"2009","unstructured":"Brunelle, J. K. & Letai, A. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell Sci. 122, 437\u2013441 (2009).","journal-title":"J. Cell Sci."},{"key":"72058_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2018.00636","volume":"8","author":"CM Adams","year":"2018","unstructured":"Adams, C. M., Clark-Garvey, S., Porcu, P. & Eischen, C. M. Targeting the Bcl-2 family in B cell lymphoma. Front. Oncol. 8, 636 (2018).","journal-title":"Front. Oncol."},{"key":"72058_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/leu.2011.378","volume":"26","author":"JM Schuetz","year":"2012","unstructured":"Schuetz, J. M. et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 26, 1383\u20131390 (2012).","journal-title":"Leukemia"},{"key":"72058_CR12","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos, L. et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091\u20133096 (1993).","journal-title":"Blood"},{"key":"72058_CR13","doi-asserted-by":"publisher","first-page":"172655","DOI":"10.1016\/j.ejphar.2019.172655","volume":"862","author":"V Suvarna","year":"2019","unstructured":"Suvarna, V., Singh, V. & Murahari, M. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. Eur. J. Pharmacol. 862, 172655 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"72058_CR14","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","volume":"7","author":"JD Leverson","year":"2017","unstructured":"Leverson, J. D. et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 7, 1376\u20131393 (2017).","journal-title":"Cancer Discov."},{"key":"72058_CR15","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1111\/febs.13815","volume":"283","author":"D Iyer","year":"2016","unstructured":"Iyer, D. et al. Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. FEBS J. 283, 3408\u20133437 (2016).","journal-title":"FEBS J."},{"key":"72058_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bcp.2016.09.028","volume":"122","author":"SV Vartak","year":"2016","unstructured":"Vartak, S. V. et al. A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis. Biochem. Pharmacol. 122, 10\u201322 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"72058_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bcp.2017.02.015","volume":"131","author":"SV Vartak","year":"2017","unstructured":"Vartak, S. V. et al. Novel BCL2 inhibitor, Disarib induces apoptosis by disruption of BCL2-BAK interaction. Biochem. Pharmacol. 131, 16\u201328 (2017).","journal-title":"Biochem. Pharmacol."},{"key":"72058_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"72058_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/0976-500X.81895","volume":"2","author":"S Parasuraman","year":"2011","unstructured":"Parasuraman, S. Toxicological screening. J. Pharmacol. Pharmacother. 2, 74\u201379 (2011).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"72058_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/2229-3485.83228","volume":"2","author":"B George","year":"2011","unstructured":"George, B. Regulations and guidelines governing stem cell based products: clinical considerations. Perspect. Clin. Res. 2, 94\u201399 (2011).","journal-title":"Perspect. Clin. Res."},{"key":"72058_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3389\/fphar.2018.01079","volume":"9","author":"H Rahalkar","year":"2018","unstructured":"Rahalkar, H., Cetintas, H. C. & Salek, S. Quality, non-clinical and clinical considerations for biosimilar monoclonal antibody development: EU, WHO, USA, Canada, and BRICS-TM regulatory guidelines. Front. Pharmacol. 9, 1079 (2018).","journal-title":"Front. Pharmacol."},{"key":"72058_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1590\/S0102-86502014000500004","volume":"29","author":"TI Restell","year":"2014","unstructured":"Restell, T. I., Porfirio, L. C., de Souza, A. S. & Silva, I. S. Hematology of Swiss mice (Mus musculus) of both genders and different ages. Acta Cir. Bras. 29, 306\u2013312 (2014).","journal-title":"Acta Cir. Bras."},{"key":"72058_CR23","first-page":"46","volume":"42","author":"LM Serfilippi","year":"2003","unstructured":"Serfilippi, L. M., Pallman, D. R. S. & Russell, B. Serum clinical chemistry and hematology reference values in outbred stocks of albino mice from three commonly used vendors and two inbred strains of albino mice. Contemp. Top. Lab. Anim. Sci. 42, 46\u201352 (2003).","journal-title":"Contemp. Top. Lab. Anim. Sci."},{"key":"72058_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang, H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14, 943\u2013951 (2007).","journal-title":"Cell Death Differ."},{"key":"72058_CR25","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1039\/C5LC00392J","volume":"15","author":"I Maschmeyer","year":"2015","unstructured":"Maschmeyer, I. et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 15, 2688\u20132699 (2015).","journal-title":"Lab Chip"},{"key":"72058_CR26","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1038\/srep06147","volume":"4","author":"M Srivastava","year":"2014","unstructured":"Srivastava, M. et al. Sapodilla plum (Achras sapota) induces apoptosis in cancer cell lines and inhibits tumor progression in mice. Sci. Rep. 4, 6147 (2014).","journal-title":"Sci. Rep."},{"key":"72058_CR27","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.cell.2012.11.054","volume":"151","author":"M Srivastava","year":"2012","unstructured":"Srivastava, M. et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 151, 1474\u20131487 (2012).","journal-title":"Cell"},{"key":"72058_CR28","doi-asserted-by":"publisher","first-page":"34653","DOI":"10.1038\/srep34653","volume":"6","author":"E Thomas","year":"2016","unstructured":"Thomas, E. et al. A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells. Sci. Rep. 6, 34653 (2016).","journal-title":"Sci. Rep."},{"key":"72058_CR29","doi-asserted-by":"publisher","first-page":"24049","DOI":"10.1038\/srep24049","volume":"6","author":"S Srivastava","year":"2016","unstructured":"Srivastava, S. et al. Quercetin, a natural flavonoid interacts with DNA, arrests cell cycle and causes tumor regression by activating mitochondrial pathway of apoptosis. Sci. Rep. 6, 24049 (2016).","journal-title":"Sci. Rep."},{"key":"72058_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mc.21867","volume":"52","author":"S Sharma","year":"2013","unstructured":"Sharma, S. et al. A novel DNA intercalator, 8-methoxy pyrimido[4\u2019,5\u2019:4,5]thieno (2,3-b)quinoline-4(3H)-one induces apoptosis in cancer cells, inhibits the tumor progression and enhances lifespan in mice with tumor. Mol. Carcinog. 52, 413\u2013425 (2013).","journal-title":"Mol. Carcinog."},{"key":"72058_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jmb.2012.01.029","volume":"417","author":"KK Chiruvella","year":"2012","unstructured":"Chiruvella, K. K. et al. Time-dependent predominance of nonhomologous DNA end-joining pathways during embryonic development in mice. J. Mol. Biol. 417, 197\u2013211 (2012).","journal-title":"J. Mol. Biol."},{"key":"72058_CR32","doi-asserted-by":"publisher","first-page":"e69103","DOI":"10.1371\/journal.pone.0069103","volume":"8","author":"CV Kavitha","year":"2013","unstructured":"Kavitha, C. V. et al. Propyl-2-(8-(3,4-difluorobenzyl)-2\u2019,5\u2019-dioxo-8-azaspiro[bicyclo[3.2.1] octane-3,4\u2019-imidazolidine]-1\u2019-yl) acetate induces apoptosis in human leukemia cells through mitochondrial pathway following cell cycle arrest. PLoS ONE 8, e69103 (2013).","journal-title":"PLoS ONE"},{"key":"72058_CR33","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1038\/s41598-017-02489-3","volume":"7","author":"M Hegde","year":"2017","unstructured":"Hegde, M. et al. A benzothiazole derivative (5g) induces DNA damage and potent G2\/M arrest in cancer cells. Sci. Rep. 7, 2533 (2017).","journal-title":"Sci. Rep."},{"key":"72058_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/carcin\/bgw081","volume":"37","author":"R Sebastian","year":"2016","unstructured":"Sebastian, R. & Raghavan, S. C. Induction of DNA damage and erroneous repair can explain genomic instability caused by endosulfan. Carcinogenesis 37, 929\u2013940 (2016).","journal-title":"Carcinogenesis"},{"key":"72058_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.2008.058248","volume":"62","author":"R Ramachandran","year":"2009","unstructured":"Ramachandran, R. & Kakar, S. Histological patterns in drug-induced liver disease. J. Clin. Pathol. 62, 481\u2013492 (2009).","journal-title":"J. Clin. Pathol."},{"key":"72058_CR36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/stem.293","volume":"28","author":"M Morigi","year":"2010","unstructured":"Morigi, M. et al. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 28, 513\u2013522 (2010).","journal-title":"Stem Cells"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72058-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:32:46Z","timestamp":1670355166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72058-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72058"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72058-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15188"}}